Skip to content
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
The 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy, took place on the 19–21 April. EMN 2018 hosted leading specialists in multiple myeloma (MM), who presented the latest research in this ever-evolving field.
Our coverage of this year’s conference includes a special interview with Robert Kyle about his work, which culminated in a much clearer understanding of the progression and risk factors for MM. Other highlights include advances in novel therapies and arguments for using patient fitness as a criterion for treatment rather than age.
Highlighted topics to explore include measurable residual disease, immunotherapy, transplantation and other monoclonal gammopathies, such as smoldering multiple myeloma, MGUS and amyloidosis. Watch those at the forefront of research cover these exciting topics right here.
150 Years of Multiple Myeloma Therapy
One of the most anticipated talks at this year’s conference was given by Robert Kyle, MD.
Prof. Kyle gives a detailed description of the history of MM, beginning with the first recorded case of the disease in the 1840’s and concluding with the developments over the years to treat this disease.
View more
Disease Biology
Investigating the mechanisms behind cancer is crucial to our ability to treat it.
EMN 2018 brought us several updates on how our understanding of cancer progression has evolved, leading us to develop therapies that are becoming more and more effective. Find out more below.
View more